Article ; Online: BDNF and its signaling in cancer.
Journal of cancer research and clinical oncology
2022 Volume 149, Issue 6, Page(s) 2621–2636
Abstract: Purpose: Brain-derived neurotrophic factor (BDNF) belongs to the family of neurotrophic factors that can potentially increase cancer cell growth, survival, proliferation, anoikis, and migration by tyrosine kinase receptors TrkB and the p75NTR death ... ...
| Abstract | Purpose: Brain-derived neurotrophic factor (BDNF) belongs to the family of neurotrophic factors that can potentially increase cancer cell growth, survival, proliferation, anoikis, and migration by tyrosine kinase receptors TrkB and the p75NTR death receptor. The activation of BDNF/TrkB pathways leads to several downstream signaling pathways, including PI3K/Akt, Jak/STAT, PLCγ, Ras-Raf-MEK-ERK, NF-kB, and transactivation of EGFR. The current review aimed to provide an overview of the role of BDNF and its signaling in cancer. Methods: We searched a major medical database, PubMed, to identify eligible studies for a narrative synthesis. Results: Pathological examinations demonstrate BDNF overexpression in human cancer, notably involving the prostate, lung, breast, and underlying tissues, associated with a higher death rate and poor prognosis. Therefore, measurement of BDNF, either for identifying the disease or predicting response to therapy, can be helpful in cancer patients. Expression profiling studies have recognized the role of microRNAs (miR) in modulating BDNF/TrkB pathways, such as miR-101, miR-107, miR-134, miR-147, miR-191, miR-200a/c, miR-204, miR-206, miR-210, miR-214, miR-382, miR-496, miR-497, miR-744, and miR-10a-5p, providing a potential biological mechanism by which targeted therapies may correlate with decreased BDNF expression in cancers. Clinical studies investigating the use of agents targeting BDNF receptors and related signaling pathways and interfering with the related oncogenic effect, including Entrectinib, Larotrectinib, Cabozantinib, Repotrectinib, Lestaurtinib, and Selitrectinib, are in progress. Conclusion: The aberrant signaling of BDNF is implicated in various cancers. Well-designed clinical trials are needed to clarify the BDNF role in cancer progression and target it as a therapeutic method. |
|---|---|
| MeSH term(s) | Male ; Humans ; Brain-Derived Neurotrophic Factor/genetics ; Brain-Derived Neurotrophic Factor/metabolism ; Phosphatidylinositol 3-Kinases/metabolism ; Cell Proliferation ; Cell Line, Tumor ; MicroRNAs/genetics ; MicroRNAs/metabolism ; Neoplasms/drug therapy ; Neoplasms/genetics |
| Chemical Substances | Brain-Derived Neurotrophic Factor ; Phosphatidylinositol 3-Kinases (EC 2.7.1.-) ; MicroRNAs ; MIRN204 microRNA, human ; MIRN206 microRNA, human ; MIRN214 microRNA, human ; MIRN496 microRNA, human ; MIRN497 microRNA, human |
| Language | English |
| Publishing date | 2022-09-29 |
| Publishing country | Germany |
| Document type | Journal Article ; Review |
| ZDB-ID | 134792-5 |
| ISSN | 1432-1335 ; 0171-5216 ; 0084-5353 ; 0943-9382 |
| ISSN (online) | 1432-1335 |
| ISSN | 0171-5216 ; 0084-5353 ; 0943-9382 |
| DOI | 10.1007/s00432-022-04365-8 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Uh III Zs.10: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.